Chester County News and Community Website
NEWTOWN, PA — Micro Interventional Devices (MID) announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Investigational Device Exemption (IDE), allowing the company to begin …
Micro Interventional Devices Secures FDA Approval to Launch Pivotal U.S. Trial for Tricuspid Valve Repair Technology Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has begun dosing participants in a Phase 2 clinical trial evaluating ratutrelvir, a ritonavir-free antiviral therapy for newly diagnosed COVID-19 patients. The …
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received the second year of funding under its U.S. Food and Drug Administration (FDA) Office of Orphan Products Development …
Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial Read More
WILMINGTON, DE — Positive results from the Phase III Bax24 trial show that baxdrostat achieved statistically significant and clinically meaningful reductions in 24-hour systolic blood pressure (SBP) among patients with …
Baxdrostat Achieves Breakthrough Blood Pressure Reductions in Phase III Bax24 Trial Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo announced that their jointly developed therapy, DATROWAY® (datopotamab deruxtecan-dlnk), achieved positive top-line results in the Phase III TROPION-Breast02 trial, marking a major advancement …
AstraZeneca and Daiichi Sankyo Report Breakthrough Results for DATROWAY® in Advanced Breast Cancer Trial Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) released new 48-week results from its Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) as a subcutaneous induction and maintenance therapy for …
Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PV™ trial evaluating rese-cel (resecabtagene autoleucel, formerly CABA-201) in patients with pemphigus vulgaris (PV) during the …
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that new data supporting the potential of Atrioventricular Interval Modulation (AVIM) Therapy in managing hypertensive heart disease, which was …
Orchestra BioMed to Highlight AVIM Therapy’s Potential to Transform Hypertension Care Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra, an investigational oral therapy for adults with moderately to …
Johnson & Johnson Reports Positive Phase 2b Results for Oral Ulcerative Colitis Therapy Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients Read More